SPARC surges after inking pact to sell Priority Review Voucher for $195 million
Sun Pharma Advanced Research Company is currently trading at Rs. 149.70, up by 1.35 points or 0.91% from its previous closing of Rs. 148.35 on the BSE.
The scrip opened at Rs. 148.05 and has touched a high and low of Rs. 163.05 and Rs. 148.05 respectively. So far 335073 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 204.25 on 02-Jun-2025 and a 52 week low of Rs. 108.20 on 23-Mar-2026.
Last one week high and low of the scrip stood at Rs. 163.05 and Rs. 114.00 respectively. The current market cap of the company is Rs. 4867.82 crore.
The promoters holding in the company stood at 65.67%, while Institutions and Non-Institutions held 2.91% and 31.42% respectively.
Sun Pharma Advanced Research Company (SPARC) has entered into a definitive asset purchase agreement to sell its Rare Paediatric Disease Priority Review Voucher (PRV) for $195 million upon the closing of the transaction. PRV was granted by the U.S. Food and Drug Administration (FDA) for the approval of Sezaby indicated for the treatment of neonatal seizures.
The transaction is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott Rodino (HSR) Antitrust Improvements Act. Stifel acted as the exclusive financial advisor to SPARC with respect to this transaction.
